GPX4 and amyotrophic lateral sclerosis: Edaravone is a clinically approved free radical scavenger for the treatment of ALS that largely inhibits ferroptosis in cystine deficiency and systemXC–/GPX4 inhibition, preventing devastating motor neuron damage (Spasić et al., 2020; Al-Chalabi et al., 2021).